Antonio Marchesoni1, Ignazio Olivieri2, Carlo Salvarani3, Nicolò Pipitone3, Salvatore D'Angelo2, Alessandro Mathieu4, Alberto Cauli4, Leonardo Punzi5, Roberta Ramonda5, Raffaele Scarpa6, Mara Maccarone7, Ennio Lubrano8. 1. Day Hospital of Rheumatology, ASST Gaetano Pini-CTO, Milano, Italy. antonio.marchesoni@asst-pini-cto.it. 2. Rheumatology Institute of Lucania, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, and Basilicata Ricerca Biomedica Foundation, Italy. 3. Azienda Ospedaliera-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Italy. 4. SC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Policlinico dell'Università di Cagliari, Italy. 5. Rheumatology Unit, Department of Medicine DIMED, University of Padova, Italy. 6. UOC di Reumatologia, Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Napoli, Italy. 7. A.DI.PSO. (Associazione per la Difesa degli Psoriasici) - PE.Pso.POF (Pan European Psoriasis Patients' Organization Forum), Roma, Italy. 8. Dipartimento di Medicina e Scienze per la Salute, Università degli Studi del Molise, Campobasso, Italy.
Abstract
OBJECTIVES: To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of biologics and other novel agents in the treatment of psoriatic arthritis (PsA). METHODS: To create this new set of recommendations, the SIR "Spondyloartritis and Psoriatic Arthritis study group - A. Spadaro" went through the following steps: literature search, identification of the items of interests for each of the four previously identified clinical domains of PsA and the different treatment phases, achievement of the consensus on all topics, and generation of the recommendations. RESULTS: An update on the available evidence on all of the biologics and new small molecules tested in PsA is reported, comprising the data for each of the individual articular manifestation. Indications for therapy inclusion criteria, choice of the drug, disease assessment, response definition, therapy failure management, and disease remission management for PsA peripheral joint arthritis, enthesitis, dactylitis, and spondylitis are provided. Suggestions for the treatment of patients with PsA and concomitant extra-articular manifestations are also given. CONCLUSIONS: These evidence-based recommendations may be used for guidance in the complex and fast-evolving field of the treatment of PsA.
OBJECTIVES: To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of biologics and other novel agents in the treatment of psoriatic arthritis (PsA). METHODS: To create this new set of recommendations, the SIR "Spondyloartritis and Psoriatic Arthritis study group - A. Spadaro" went through the following steps: literature search, identification of the items of interests for each of the four previously identified clinical domains of PsA and the different treatment phases, achievement of the consensus on all topics, and generation of the recommendations. RESULTS: An update on the available evidence on all of the biologics and new small molecules tested in PsA is reported, comprising the data for each of the individual articular manifestation. Indications for therapy inclusion criteria, choice of the drug, disease assessment, response definition, therapy failure management, and disease remission management for PsA peripheral joint arthritis, enthesitis, dactylitis, and spondylitis are provided. Suggestions for the treatment of patients with PsA and concomitant extra-articular manifestations are also given. CONCLUSIONS: These evidence-based recommendations may be used for guidance in the complex and fast-evolving field of the treatment of PsA.
Authors: Roberta Ramonda; Mariagrazia Lorenzin; Antonio Carriero; Maria Sole Chimenti; Raffaele Scarpa; Antonio Marchesoni; Ennio Lubrano di Scorpaniello; Carlo Salvarani; Alberto Cauli; Angelo Semeraro; Leonardo Santo; Augusta Ortolan; Andrea Doria; Elena Fracassi; Giulia Virelli; Marco Masia; Rosalinda Fanizzi; Elisa Visalli; Giorgio Amato; Antonio Carletto; Rosario Foti Journal: RMD Open Date: 2021-02